$125.69
0.22% yesterday
Nasdaq, Jun 30, 10:01 pm CET
ISIN
US64125C1099
Symbol
NBIX

Neurocrine Biosciences, Inc. Stock price

$125.69
+2.67 2.17% 1M
-11.37 8.30% 6M
-10.81 7.92% YTD
-14.42 10.29% 1Y
+28.21 28.94% 3Y
+3.69 3.02% 5Y
+77.93 163.17% 10Y
+83.63 198.84% 20Y
Nasdaq, Closing price Mon, Jun 30 2025
+0.27 0.22%
ISIN
US64125C1099
Symbol
NBIX
Sector
Industry

Key metrics

Basic
Market capitalization
$12.4b
Enterprise Value
$11.5b
Net debt
positive
Cash
$943.5m
Shares outstanding
99.0m
Valuation (TTM | estimate)
P/E
42.09 | 31.31
P/S
5.14 | 4.53
EV/Sales
4.75 | 4.19
EV/FCF
23.30
P/B
4.90
Financial Health
Equity Ratio
69.64%
Return on Equity
13.18%
ROCE
15.84%
ROIC
13.62%
Debt/Equity
0.00
Financials (TTM | estimate)
Revenue
$2.4b | $2.7b
EBITDA
$529.9m | $596.2m
EBIT
$501.4m
Net Income
$305.8m | $396.6m
Free Cash Flow
$492.2m
Growth (TTM | estimate)
Revenue
21.73% | 16.29%
EBITDA
7.51% | -2.28%
EBIT
6.59%
Net Income
-17.28% | 16.21%
Free Cash Flow
-19.89%
Margin (TTM | estimate)
Gross
98.52%
EBITDA
21.96% | 21.77%
EBIT
20.78%
Net
12.68% | 14.48%
Free Cash Flow
20.40%
More
EPS
$2.98
FCF per Share
$4.97
Short interest
4.72%
Employees
1.80k
Rev per Employee
$1.31m
Show more

Is Neurocrine Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,948 stocks worldwide.

Neurocrine Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

32 Analysts have issued a Neurocrine Biosciences, Inc. forecast:

27x Buy
84%
5x Hold
16%

Analyst Opinions

32 Analysts have issued a Neurocrine Biosciences, Inc. forecast:

Buy
84%
Hold
16%

Financial data from Neurocrine Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
2,413 2,413
22% 22%
100%
- Direct Costs 36 36
8% 8%
1%
2,377 2,377
22% 22%
99%
- Selling and Administrative Expenses 1,041 1,041
17% 17%
43%
- Research and Development Expense 835 835
43% 43%
35%
530 530
8% 8%
22%
- Depreciation and Amortization 29 29
27% 27%
1%
EBIT (Operating Income) EBIT 501 501
7% 7%
21%
Net Profit 306 306
17% 17%
13%

In millions USD.

Don't miss a Thing! We will send you all news about Neurocrine Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Neurocrine Biosciences, Inc. Stock News

Neutral
PRNewsWire
about 6 hours ago
SAN DIEGO , June 30, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of investigational compound NBIP-01435 in healthy adult participants. NBIP-01435 is a long-acting corticotropin-releasing factor type 1 receptor ...
Positive
MarketBeat
one day ago
With the notable exceptions of Novo Nordisk A/S NYSE: NVO and Eli Lilly & Co. NYSE: LLY, biotechnology stocks had a rough time attracting investment capital in 2024. Small- and mid-cap biotech stocks struggled to raise capital in a higher-for-longer interest rate environment.
Neutral
PRNewsWire
4 days ago
Patient-reported analyses demonstrated greater reduction in both cognitive and motor-related disease burden for INGREZZA compared with placebo Findings to be presented at the 2025 Advanced Therapeutics in Movement & Related Disorders (ATMRD) Congress SAN DIEGO , June 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new patient-reported post-hoc data from the ...
More Neurocrine Biosciences, Inc. News

Company Profile

Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.

Head office United States
CEO Kyle Gano
Employees 1,800
Founded 1992
Website www.neurocrine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today